OrsoBio

Palo Alto, United States

OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.

$67.0M raised

Sep 2024

Series B

Top Investors

Eli LillySamsara BioCapitalLongitude CapitalEnavate SciencesWoodline Partners

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has OrsoBio raised?

OrsoBio has raised $67.0M in total funding. The most recent round was Series B. The last funding was announced in September 2024.

Who are OrsoBio's investors?

OrsoBio's investors include Eli Lilly, Samsara BioCapital, Longitude Capital, Enavate Sciences, Woodline Partners.

Where is OrsoBio headquartered?

OrsoBio is headquartered in Palo Alto, United States.

What does OrsoBio do?

OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders.

What stage is OrsoBio at?

OrsoBio is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 6, 2024.

MLA

"OrsoBio — Funding & Investors." VCBacked, September 6, 2024, https://www.vcbacked.co/company/orsobio. Accessed June 14, 2026.

APA

VCBacked. (2024). OrsoBio — Funding & Investors. Retrieved June 14, 2026, from https://www.vcbacked.co/company/orsobio

Wikipedia (cite web)

{{cite web |title=OrsoBio — Funding & Investors |url=https://www.vcbacked.co/company/orsobio |website=VCBacked |access-date=June 14, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 6, 2024.